RCUSArcus Biosciences, Inc.Finished
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
Advanced Upper Gastrointestinal Tract Adenocarcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 1,040 (final count)
- Started
- Nov 21, 2022
- Main results expected
- Aug 28, 2026
- Fully finished
- Aug 28, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall survival
Measured over: From date of randomization until date of death from any cause (Approximately 15 months)]
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05568095 · record last updated 2026-09-03 · checked 2026-11-09 15:47 UTC